Viatris (VTRS) Non-Current Assets (2019 - 2026)
Viatris' (VTRS) quarterly Non-Current Assets came in at $25.9 billion in Q1 2026, down 10.17% year-on-year from $28.9 billion in Q1 2025, and down 5.42% quarter-over-quarter from $27.4 billion in Q4 2025.
Viatris (VTRS) Non-Current Assets (2019 - 2026) Analysis & Trends
Viatris' Non-Current Assets history runs 8 years deep, the most recent figure standing at $25.9 billion for Q1 2026.
- On a quarterly basis, Non-Current Assets fell 10.17% year-over-year to $25.9 billion in Q1 2026; TTM through Mar 2026 was $109.9 billion, a 14.0% decrease from a year earlier, with the FY2025 full-year figure at $27.4 billion, down 14.31% from the prior year.
- Non-Current Assets slipped to $25.9 billion in Q1 2026 per VTRS's latest filing, from $27.4 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $41.7 billion in Q1 2022 and bottomed at $25.9 billion in Q1 2026.
- The 5-year median for Non-Current Assets is $34.4 billion (2024), against an average of $34.3 billion.
- Across the five-year window, Non-Current Assets jumped 7877260.0% in 2022 and retreated 16.38% in 2025, its largest moves.
- Year by year, Non-Current Assets stood at $39.4 billion in 2022, then decreased by 11.88% to $34.7 billion in 2023, then declined by 7.86% to $32.0 billion in 2024, then dropped by 14.31% to $27.4 billion in 2025, then retreated by 5.42% to $25.9 billion in 2026.
- Per Business Quant, the three latest VTRS Non-Current Assets figures stand at $25.9 billion (Q1 2026), $27.4 billion (Q4 2025), and $28.0 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 670.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.92 Bn |
| Dec 31, 2025 | 27.40 Bn |
| Sep 30, 2025 | 27.97 Bn |
| Jun 30, 2025 | 28.64 Bn |
| Mar 31, 2025 | 28.85 Bn |
| Dec 31, 2024 | 31.98 Bn |
| Sep 30, 2024 | 33.45 Bn |
| Jun 30, 2024 | 33.54 Bn |
| Mar 31, 2024 | 34.42 Bn |
| Dec 31, 2023 | 34.71 Bn |
| Sep 30, 2023 | 37.81 Bn |
| Jun 30, 2023 | 38.92 Bn |
| Mar 31, 2023 | 39.66 Bn |
| Dec 31, 2022 | 39.39 Bn |
| Sep 30, 2022 | 38.17 Bn |
| Jun 30, 2022 | 39.95 Bn |
| Mar 31, 2022 | 41.72 Bn |
| Dec 31, 2021 | 500,000.00 |
| Sep 30, 2021 | 44.76 Bn |
| Jun 30, 2021 | 46.23 Bn |